- Home
- XERS vs BCAL Comparison
XERS vs BCAL Comparison
Compare XERS & BCAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- BCAL
- Stock Information
- Founded
- XERS 2005
- BCAL 2001
- Country
- XERS United States
- BCAL United States
- Employees
- XERS N/A
- BCAL N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- BCAL Major Banks
- Sector
- XERS Health Care
- BCAL Finance
- Exchange
- XERS Nasdaq
- BCAL Nasdaq
- Market Cap
- XERS 526.3M
- BCAL 503.4M
- IPO Year
- XERS 2018
- BCAL N/A
- Fundamental
- Price
- XERS $3.70
- BCAL $15.75
- Analyst Decision
- XERS Buy
- BCAL Strong Buy
- Analyst Count
- XERS 3
- BCAL 1
- Target Price
- XERS $4.87
- BCAL $20.00
- AVG Volume (30 Days)
- XERS 1.6M
- BCAL 67.0K
- Earning Date
- XERS 03-05-2025
- BCAL 01-29-2025
- Dividend Yield
- XERS N/A
- BCAL N/A
- EPS Growth
- XERS N/A
- BCAL N/A
- EPS
- XERS N/A
- BCAL 0.22
- Revenue
- XERS $187,361,000.00
- BCAL $106,054,000.00
- Revenue This Year
- XERS $24.64
- BCAL N/A
- Revenue Next Year
- XERS $19.04
- BCAL $48.22
- P/E Ratio
- XERS N/A
- BCAL $72.50
- Revenue Growth
- XERS 22.72
- BCAL 9.78
- 52 Week Low
- XERS $1.69
- BCAL $12.30
- 52 Week High
- XERS $3.87
- BCAL $18.49
- Technical
- Relative Strength Index (RSI)
- XERS 62.63
- BCAL 50.90
- Support Level
- XERS $3.47
- BCAL $14.80
- Resistance Level
- XERS $3.78
- BCAL $17.29
- Average True Range (ATR)
- XERS 0.16
- BCAL 0.60
- MACD
- XERS 0.03
- BCAL 0.19
- Stochastic Oscillator
- XERS 84.13
- BCAL 46.18
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through strong partnerships with its clients.